Actively Recruiting
Phase 12a Study of BI-1206 with Rituximab With or Without Acalabrutinib for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma
Led by BioInvent International AB · Updated on 2026-10-02
140
Participants Needed
27
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BI-1206, a monoclonal antibody targeting CD32b, in combination with rituximab with or without acalabrutinib in adults with indolent B-cell Non-Hodgkin Lymphoma NHL that has relapsed or is resistant to rituximab. This Phase 12a, multicenter, open-label trial includes patients with follicular lymphoma except grade 3B, marginal zone lymphoma, and mantle cell lymphoma. The study involves dose escalation, signal seeking, and dose optimization phases to find the recommended BI-1206 dose. The study has two main parts Phase 1 involves dose escalation cohorts testing intravenous IV and subcutaneous SC BI-1206 combined with rituximab to determine safe doses. Phase 2a includes dose expansion of the selected IV dose with rituximab, signal seeking cohorts testing BI-1206 with rituximab and acalabrutinib both IV and SC, and a randomized dose optimization phase to select the best BI-1206 dose in combination with these drugs. Participants receive BI-1206 by injection or infusion, rituximab by infusion, and acalabrutinib orally. During the study, participants undergo safety monitoring, including tracking adverse events and determining dose-limiting toxicities over a 28-day induction period. Researchers assess pharmacokinetics, immune responses, B-cell depletion, and overall treatment response for up to one year. Participants are evaluated regularly with biopsies, blood tests, and clinical assessments to monitor disease status and treatment effects. The total duration depends on the study phase and dosing schedule, with ongoing safety and efficacy evaluations planned through 2027.
CONDITIONS
Brief Title
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Research Team
E
Erika Bågeman
A
Andres McAllister, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here